Dec 16 2009
Sunwin International Neutraceuticals, Inc.
(OTCBB: SUWN) today reported results for the fiscal 2010 second quarter
ended October 31, 2009.
Total revenue was $3.7 million compared to $3.4 million in the first fiscal
quarter of 2010 and $6.6 million in the same quarter of the prior fiscal
year. The year-over-year decline was primarily a result of declines in the
natural medicines segment related to weather and breeding limitations in
the People's Republic of China and lower sales of Stevia due a reduction in
customer demand as result of a slow recovery from the overall world
economic crisis and declines in the South Korean Won. Year-to-date, total
revenue was $7.0 million compared to $12.8 million, including $5.4 in
stevia extract sales and $1.8 million in natural medicines as compared to
$7.7 million in Stevia sales and $5.1 million in natural medicines in the
same period of the prior fiscal year. Total sales were up 10% from the
first quarter, primarily driven by initial recovery in the Stevia extract
business. Operating expenses were $0.8 million as compared to $1.1 million
a year ago due to cost cutting initiatives, partially offset by startup
costs related to the company's new high-grade extracts and production
facilities. Net loss was $0.2 million, or $0.00 per share, compared to net
income of $0.4 million, or $0.00 per share, in the same quarter in the
prior fiscal year.
"Fiscal 2010 began during a difficult period for the global economy as many
of our customers had reduced production levels following a very strong
2009," commented Laiwang Zhang, the company's Chairman. "Our second quarter
results were affected by these challenges, but we are beginning to see
signs of recovery in our broader end markets. During this time, we have
utilized our strong balance sheet to invest in increased production
facilities for Rebaudioside A 98 using cash rather than debt. As a result,
we are now able to provide the high grade of Stevia extract into an
expanding market without being tied to the success of any one end market or
ingredient provider. We believe that the addition of production capacity
for Rebaudioside A 98 will position the company for increased Stevia sales
ahead."
On the balance sheet at October 31, 2009, cash increased slightly to $10.6
million from $10.5 million at April 30, 2009. Inventory was $7.1 million
compared to $7.7 million at prior fiscal year-end, including approximately
$4.1 million in finished goods.
As a primary provider of Stevia extract in Asia, our sales in the second
quarter of fiscal 2010 were affected by the global economic slowdown and a
decrease in the value of the South Korean Won compared to the Chinese
Renminbi, which has reduced sales of certain Chinese goods to this region,
a key Stevia market. Veterinary sales were affected negatively by flooding
in southern China earlier in calendar 2009 as well as government
restrictions on livestock breeding. We have increased our domestic Chinese
stevia sales focus and continue to develop opportunities in the growing
North American marketplace where in September 2009 we completed the process
for U.S. Food and Drug Administration ("FDA") self-affirmed GRAS status for
certain stevia extracts we produce. Also, we completed construction of our
new high-grade stevia extracts and production facilities in the second
quarter of fiscal 2010 which increased production capacity to 500 metric
tons.
"Our announcement of self-affirmed GRAS status in September 2009 opened the
door for a number of US and North American opportunities for our Stevia
products, especially in conjunction with our development partner WILD
Flavors, one of the top natural foods development companies worldwide,"
said Jeff Reynolds, President and CEO of Sunwin USA. "The increasing
interest in Stevia as a natural, no calorie sweetening system presents
numerous opportunities for Sunwin. We are able to not only supply extract,
but also work directly with the customer to address their unique
formulation needs of producing quality food and beverage products matching
specific taste and price profiles. There are a number of products with
international food and beverage companies that are being readied for market
with more in development. We are very excited for the opportunities ahead
in the Stevia business."
SOURCE: Sunwin International Neutraceuticals, Inc.